Notification of major interests in shares

RNS Number : 1313B
Hikma Pharmaceuticals Plc
27 February 2014
 

 

Notification of major interests in shares

 

LONDON, 27 February 2014 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:

 

1

Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached

Hikma Pharmaceuticals PLC

 

 

 

2

Reason for the notification



An acquisition or disposal of voting rights

Yes


An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached

No


An event changing the breakdown of voting rights

No


Other (please specify): Compliance with the Transparency Directive

No

 

 

3

Full name of the person subject to the notification obligation

The Capital Group Companies, Inc

4

Full name of shareholders

Capital Research and Management Company New World Fund, Inc

5

Date of the Transaction (and date on which the threshold crossed is reached differently)

25 February 2014

6

Date on which the issuer notified

26 February 2014

7

Threshold that is crossed

10%

8

Notified details

See A, B & C below




A. Voting rights attached to shares

Class type of shares (if possible using the ISIN code)

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of shares

Number of voting rights

Number of shares

Number of voting rights

% of voting rights

Direct

Indirect

Direct

Indirect

Direct

Indirect

Ordinary Shares (0.10 GBP)

GB00B0LCW083

19,807,981

19,807,981

0

19,232,981

0

19,232,981

0%

9.719%

 

B. Qualifying Financial instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration Date

Exercise/Conversion Period/Date

Number of voting rights that may be acquired if the instrument if exercised/converted

% of voting rights

-

-

-

-

-

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise Price

Expiration Date

Exercise/Conversion Period/Date

Number of voting rights instrument refers to

% of voting rights

Nominal           

Delta

-

-

-

-

-

-

-

 

Total A+B+C

Number of Voting rights

% of voting rights

19,232,981

9.719

 

9

Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable



 

Proxy Voting

10

Name of the proxy holder

The Capital Group Companies, Inc

11

Number of voting rights proxy holder will cease to hold

N/A

12

Date on which proxy holder will cease to hold voting rights

N/A

 

13

Additional Information


14

Contact name:

Peter Speirs, Company Secretary

15

Contact telephone number:

020 7399 2772

 

- ENDS -



About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million. 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUBOSRSOAUUAR
UK 100

Latest directors dealings